Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Executive Summary
Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said
You may also be interested in...
Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy
Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy
Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys
Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3